NEW ORLEANS, Louisiana — An experimental new drug for glaucoma and ocular hypertension is as effective as latanoprost but causes different adverse events, the results of a phase 3 clinical trial ...

Please provide your email address to receive an email when new articles are posted on . Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients ...

Dear Dr. Gott: I am a 78-year-old white male. I use glasses that cost $1 to read sometimes. I have been seen by two doctors. Both say I have glaucoma. Both doctors said to use Xalatan at bedtime for ...

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9200651-thea-pharma-inc-launches-iyuzeh/ "The U.S. launch of ...

Prostaglandin analogues, such as latanoprost and bimatoprost, are the go-to therapies for glaucoma therapy. They continue to ...

Fort Lauderdale, Florida (May 8, 2002) – Switching to XALATAN® (latanoprost ophthalmic solution) once daily from monotherapy with other medications, including prostaglandin derivatives, for open angle ...

Peapack, New Jersey (May 2, 2002) - Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with ...

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...

A new glaucoma drug, latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta™), was approved by the US Food and Drug Administration in November 2017. Key to its approval was the VOYAGER Study.

WASHINGTON (Reuters) - For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global ...